Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $65.64 and last traded at $64.40, with a volume of 337436 shares traded. The stock had previously closed at $66.00.
Neoleukin Therapeutics Price Performance
The firm has a market capitalization of $605.23 million, a price-to-earnings ratio of -21.22 and a beta of 1.11. The firm’s 50-day simple moving average is $43.98 and its 200 day simple moving average is $38.91.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Palantir Cracks $50, Is There Still Time to Get on Board?
- The Significance of Brokerage Rankings in Stock Selection
- Insider Buying Signals Upside for These 3 Stocks
- What Are Dividend Contenders? Investing in Dividend Contenders
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}